$652 Million is the total value of Kynam Capital Management, LP's 31 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CNTB | CONNECT BIOPHARMA HLDGS LTDads | $641,867 | -32.7% | 739,649 | 0.0% | 0.10% | -51.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
VAXCYTE INC | 8 | Q3 2023 | 10.9% |
VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
SC 13G/A | 2024-03-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-02-14 |
SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.